Apcegen
Biopharmaceutical company focused on developing affordable biologic therapeutics and regenerative medicine approaches. The organization emphasizes pathway engineering, antibody and biologics platform development, cell line and process development, analytical method development, and translation of discovery research into manufacturing-ready technologies for autoimmune disease, oncology (immuno-oncology), metabolic disease, and cardiovascular tissue engineering.
Industries
Nr. of Employees
small (1-50)
Apcegen
B901 Daadys Elixir, Near APMC fruit Market, Electronic City - II, Bangalore, Karnataka 560100, India
Products
Biosimilars
Pipeline work and platform capabilities to develop biosimilar therapeutic proteins.
Alternate/novel biologics
Development of alternate or novel biologic candidates targeting autoimmune and inflammatory pathways.
Regenerative medicine products
Research-stage regenerative-medicine approaches, including nanofiber-based cardiovascular tissue engineering.
Biosimilars
Pipeline work and platform capabilities to develop biosimilar therapeutic proteins.
Alternate/novel biologics
Development of alternate or novel biologic candidates targeting autoimmune and inflammatory pathways.
Regenerative medicine products
Research-stage regenerative-medicine approaches, including nanofiber-based cardiovascular tissue engineering.
Services
Development of mammalian and microbial expression systems for recombinant proteins and antibodies.
Early- and late-stage process development to optimize yield and product quality for biologics.
Engineering and platform development for antibody-based therapeutics and biosimilars.
Development and validation of analytical assays and orthogonal characterization techniques for proteins and antibodies.
Development work on nanofiber-based cardiovascular tissue engineering approaches.
Development of mammalian and microbial expression systems for recombinant proteins and antibodies.
Early- and late-stage process development to optimize yield and product quality for biologics.
Engineering and platform development for antibody-based therapeutics and biosimilars.
Development and validation of analytical assays and orthogonal characterization techniques for proteins and antibodies.
Development work on nanofiber-based cardiovascular tissue engineering approaches.
Expertise Areas
- Cell line development
- Bioprocessing and scale-up
- Antibody engineering and biologics development
- Analytical method development and protein characterization
Key Technologies
- Mammalian cell expression systems (CHO-based)
- Microbial periplasmic expression systems
- Antibody engineering platforms
- Bioprocess scale-up and production process development
News & Updates
Received seed support from a government technology development body; developed a mammalian expression platform and received approval for a fusion-protein project under a technology program.
Progressed an alternate therapy drug candidate focused on TNF-related autoimmune disorders.
Received a government grant for the autoimmune therapy candidate and developed additional platform technologies.
Signed memoranda of understanding with external organizations and received an industry award as an outstanding performer in biopharma.
Received seed support from a government technology development body; developed a mammalian expression platform and received approval for a fusion-protein project under a technology program.
Progressed an alternate therapy drug candidate focused on TNF-related autoimmune disorders.
Received a government grant for the autoimmune therapy candidate and developed additional platform technologies.
Signed memoranda of understanding with external organizations and received an industry award as an outstanding performer in biopharma.